Muddled Picture for Antidepressant as Osteoarthritis Pain Reliever Trial in primary care setting fails to confirm benefit seen in specialty clinics Jan 06, 2022
Success for Upadacitinib in PsA, Despite Concerns JAK inhibitor nabs new indication after FDA called for boxed warnings on the class Dec 28, 2021
Hydroxychloroquine Linked to Less Heart Risk in RA, Lupus Current use of the antimalarial especially was particularly associated with less thrombosis Dec 28, 2021
Another Trial, Another PRP Flop in Osteoarthritis Fails to outperform saline in randomized trial Nov 23, 2021
Another Study Confirms Gout Benefit With SGLT2 Inhibitors Gout risk reduction was significantly better than with DPP-4 inhibitors Nov 19, 2021
Biologic Disappoints for Arthritis Achilles' Inflammation But phase III trial did find some patient-oriented benefits Nov 11, 2021
For Systemic JIA, Start Biologics Early Observational study shows excellent efficacy in systemic pediatric arthritis Nov 10, 2021
HAE Still Drawing Attention From Drugmakers Two new products show midstage promise in hereditary angioedema Nov 10, 2021
Secukinumab: An Up-and-Coming Option in Giant Cell Arteritis? Phase II trial found sustained remission with steroid-sparing effects Nov 10, 2021
Voclosporin Benefits in Nephritis Persist at 30 Months No new safety signals seen in long-term extension for lupus nephritis Nov 09, 2021
Avacopan Helps Vasculitis Patients With Renal Impairment Wean Off Steroids Patients saw better eGFR recovery compared with prednisone Nov 08, 2021
Vitamin D and Disease Prevention: Worth Another Look? Incidence of autoimmune disease decreased by 25-30% with dietary supplements Nov 08, 2021
Guselkumab Response Durable in Psoriatic Arthritis Skin and joint improvements persisted through 2 years of follow-up Nov 08, 2021
Early Biologics Better in Juvenile Idiopathic Arthritis After 2 years, more patients on combo biologic/DMARD regimen had inactive disease Nov 08, 2021
Brepocitinib Shows Promise in Phase II Trial for PsA Oral tyrosine kinase 2/JAK-1 inhibitor improved both joint and skin manifestations Nov 07, 2021
Could This Biologic Drug Work in Patients Lacking Its Target? Bizarre finding with omalizumab Nov 07, 2021
Targeting IL-23 Succeeds in Psoriatic Arthritis Patients had active, longstanding disease and inadequate responses to other agents Nov 07, 2021
Can Abatacept Reverse Early Rheumatoid Arthritis? At-risk patients showed improvements in inflammation -- and also delays in disease onset Nov 06, 2021
Mixed Results With Anti-Interleukin Biologics in Asthma One shows promise; another fails miserably (and mysteriously) Oct 27, 2021
No Love for PRP in Ankle Osteoarthritis Trial Dutch researchers throw cold water on popular therapy Oct 26, 2021
Following Rituximab With Second Biologic Helpful in Lupus Trial may provide answer for patients who don't respond to B-cell depletion Oct 25, 2021
How Should Patients With Autoimmune Diseases Approach COVID Vaccination? Mixed messaging and a lack of tailored research leaves providers and patients in the dark Oct 22, 2021
First Interchangeable Humira Biosimilar Approved Cyltezo nabs coveted "interchangeable" status for RA, inflammatory bowel disease, and more Oct 18, 2021
FDA Gives Thumbs Up to ANCA-Associated Vasculitis Drug Approval granted to avacopan despite advisory committee concerns Oct 08, 2021
Is This the Future of Corticosteroids? Novel agent, aimed at doing away with adverse metabolic effects, proves mettle in DMD Oct 05, 2021
Olfactory Loss Common in Sjogren's Syndrome Objective impairments in olfaction correlated with disease activity and symptoms Sep 29, 2021
In RA, Little Risk for Recurrent Cancer With Biologic Treatment Results important because most trials excluded patients with previous cancer, researchers note Sep 23, 2021
Statins Not Linked With Rheumatoid Arthritis, Large Study Finds Risks attenuated after adjustment for lipid levels Sep 22, 2021
IBD and Pediatric Arthritis: Exploring the Link Risk factors include enthesitis, family history, and etanercept use Sep 15, 2021
Pneumocystis Often Lethal in Dermatomyositis Incidence of pneumonia high in MDA5-antibody-positive patients Sep 10, 2021
Lymphoma in RA: Disease Activity Matters Strongest risk factors were baseline disease activity scores and bone erosions Sep 08, 2021
FDA Slaps Restrictions on JAK Inhibitors Over Serious Safety Risks Use for inflammatory conditions limited to those who fail on TNF blockers Sep 01, 2021
Fibromyalgia: A New Feature of Long COVID? Almost one-third of patients in Italian study had musculoskeletal sequelae Aug 31, 2021
What's Causing Cancer Patient's Joint Pain While on Checkpoint Inhibitor? Here is how clinicians diagnosed this rare inflammatory side effect Aug 30, 2021
What Factors Predict RA in First-Degree Relatives? Study may offer insight into preclinical phase to identify factors that predict progression Aug 12, 2021
Healthy Lifestyle Limits Lupus Risk Diet, exercise, weight, smoking, and moderate alcohol use contributed to lower risk in women Jul 29, 2021
New-Onset IBD and IL-17 Inhibitors: What Is the Risk? Underlying inflammatory disease severity should be taken into account Jul 21, 2021
FDA Approves IVIG for Dermatomyositis Octagam 10% lands indication for adults following results of ProDERM trial Jul 20, 2021
CV Risk in PsA: Do Drugs Matter? Study weighs in on heart safety of TNF inhibitors versus other biologics Jul 19, 2021
